ArticleJournal of cheminformatics2020
Industry-scale application and evaluation of deep learning for drug target prediction.
Article in Journal of cheminformatics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Artificial intelligence drives the identification and screening of novel antibiotics and antimicrobial peptides.Briefings in bioinformatics · 2026Review
- Toward Smarter Orthopedic Care: Classifying Plantar Footprints from RGB Images Using Vision Transformers and CNNs.Journal of imaging · 2025Article
- MHNfs: Prompting In-Context Bioactivity Predictions for Low-Data Drug Discovery.Journal of chemical information and modeling · 2025Article
- The Present State and Potential Applications of Artificial Intelligence in Cancer Diagnosis and Treatment.Recent patents on anti-cancer drug discovery · 2025Review
- GT-NMR: a novel graph transformer-based approach for accurate prediction of NMR chemical shifts.Journal of cheminformatics · 2024Article
- Testing the predictive power of reverse screening to infer drug targets, with the help of machine learning.Communications chemistry · 2024Article
- Translation of genome-wide association study: from genomic signals to biological insights.Frontiers in genetics · 2024Review
- A general prediction model for compound-protein interactions based on deep learning.Frontiers in pharmacology · 2024Article
- CLOOME: contrastive learning unlocks bioimaging databases for queries with chemical structures.Nature communications · 2023Article
- In silico Methods for Identification of Potential Therapeutic Targets.Interdisciplinary sciences, computational life sciences · 2022Review
- A human-based multi-gene signature enables quantitative drug repurposing for metabolic disease.eLife · 2022Article
- Clinical applications of artificial intelligence and machine learning in cancer diagnosis: looking into the future.Cancer cell international · 2021Review
- Memory-assisted reinforcement learning for diverse molecular de novo design.Journal of cheminformatics · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
Abstract
Artificial intelligence (AI) is undergoing a revolution thanks to the breakthroughs of machine learning algorithms in computer vision, speech recognition, natural language processing and generative modelling. Recent works on publicly available pharmaceutical data showed that AI methods are highly promising for Drug Target prediction. However, the quality of public data might be different than that of industry data due to different labs reporting measurements, different measurement techniques, fewer samples and less diverse and specialized assays. As part of a European funded project (ExCAPE), that brought together expertise from pharmaceutical industry, machine learning, and high-performance computing, we investigated how well machine learning models obtained from public data can be transferred to internal pharmaceutical industry data. Our results show that machine learning models trained on public data can indeed maintain their predictive power to a large degree when applied to industry data. Moreover, we observed that deep learning derived machine learning models outperformed comparable models, which were trained by other machine learning algorithms, when applied to internal pharmaceutical company datasets. To our knowledge, this is the first large-scale study evaluating the potential of machine learning and especially deep learning directly at the level of industry-scale settings and moreover investigating the transferability of publicly learned target prediction models towards industrial bioactivity prediction pipelines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.